Recently, the tumor-selective action of histone deacetylase inhibitors (HDACi) was shown to involve TRAIL induction in acute myeloid leukemia cells [9], [10], paving the road to drug-based antitumor therapeutic strategies targeting TNFSF functions. This evidence concerns the gene TNFSF10 and neoplasm.